Stratagen Bio

Active dates: 

January 20, 2023 - January 20, 2023

STEX25

STEX25 Participation:

January 20, 2023 - June 30, 2024

Company information

Elevator Pitch

Stratagen Bio is transforming MRI into a tool for quantitative biomarker assessment and objective clinical decision making.

Description

Tumor hypoxia is characterized by extremely low levels of oxygen (<15.2 mmHg/2% O2). It occurs in fifty percent1 of all tumors and is a well-established negative prognostic indicator. Poor outcomes are seen in patients with hypoxic tumors in cancers including breast, cervical, head and neck, soft tissue sarcomas, pancreatic, and prostate. These patients suffer from higher relapse rates and lower survival rates than those with more well-oxygenated tumors. These poor outcomes are driven by resistance to treatment in hypoxic tumors. Beyond patients and clinicians, it is critical for companies developing new therapies targeting hypoxic tumors to properly identify patients for their treatments.

Technology Description

Our first product, the OxyTrack platform, is a proprietary tissue oxygen sensor, treatment guidance software, and AI-enabled oxygen data engine. Our platform enables clinicians to incorporate direct and absolute measurements of tissue oxygen in their treatment planning process which isn’t currently possible. Our OxyTrack platform can be used to personalize care and improve outcomes beyond cancer in applications including trauma, ischemic injuries, and vascular disorders. Our OxyTrack sensors are fiducial marker sized, provide an absolute and direct measurement of tissue oxygen, and are read using commercial MRI sequences and scanners. The sensors are made completely of medical-grade silicone and are placed using minimally invasive methods that are standard of care for the placement of fiducial markers and brachytherapy seeds.